Implications of pharmacogenetics for individualizing drug treatment and for study design

[1]  Yoshinori Morita,et al.  MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects , 2001, Pharmaceutical Research.

[2]  M. Eichelbaum,et al.  Defective N-oxidation of sparteine in man: A new pharmacogenetic defect , 1979, European Journal of Clinical Pharmacology.

[3]  R. Bönicke,et al.  Über die Erbbedingtheit der intraindividuellen Konstanz der Isoniazidausscheidung beim Menschen (Untersuchungen an eineiigen und zweieiigen Zwillingen) , 2004, Naturwissenschaften.

[4]  Christian Meisel,et al.  MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. , 2002, British journal of clinical pharmacology.

[5]  U. Brinkmann,et al.  Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene , 2002, Clinical pharmacology and therapeutics.

[6]  S. Kardia,et al.  Synergistic Polymorphisms of β1- and α2C-Adrenergic Receptors and the Risk of Congestive Heart Failure , 2002 .

[7]  U. Hofmann,et al.  MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. , 2002, British journal of clinical pharmacology.

[8]  Wolfgang Rohde,et al.  Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers , 2002, Clinical pharmacology and therapeutics.

[9]  J. Goldstein,et al.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.

[10]  M. Kasuga,et al.  Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects , 2002, Clinical pharmacology and therapeutics.

[11]  D. Flockhart,et al.  Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. , 2002, Pharmacogenetics.

[12]  C. Meisel,et al.  Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. , 2002, Pharmacogenetics.

[13]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[14]  M. Mascelli,et al.  Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. , 2002, American heart journal.

[15]  M. Zago,et al.  Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. , 2002, Haematologica.

[16]  J. Goldstein,et al.  Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. , 2001, Pharmacogenetics.

[17]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[18]  R. Kim,et al.  The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. , 2001, The New England journal of medicine.

[19]  S. Kasper,et al.  CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages , 2001, Acta psychiatrica Scandinavica.

[20]  R. Kim,et al.  Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. , 2001, Molecular pharmacology.

[21]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[22]  M. Fromm,et al.  The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. , 2001, Pharmacogenetics.

[23]  G. MacGowan,et al.  Pharmacogenetic Interactions Between &bgr;-Blocker Therapy and the Angiotensin-Converting Enzyme Deletion Polymorphism in Patients With Congestive Heart Failure , 2001, Circulation.

[24]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[25]  S. Liggett.  Pharmacogenetic applications of the Human Genome project , 2001, Nature Medicine.

[26]  M. I. Ngelman-Sundber.  Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy , 2001 .

[27]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[28]  Michael Zschiesche,et al.  Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction , 2000, Clinical pharmacology and therapeutics.

[29]  M. Daly,et al.  Guilt by association , 2000, Nature Genetics.

[30]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R S Judson,et al.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Hall,et al.  A comparison of molecular and enzyme‐based assays for the detection of thiopurine methyltransferase mutations , 2000, British journal of haematology.

[33]  Eric S. Lander,et al.  The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes , 2000, Nature Genetics.

[34]  E. Silverman,et al.  The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. , 2000, American journal of respiratory and critical care medicine.

[35]  C. Meisel,et al.  Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. , 2000, Pharmacogenomics.

[36]  W. Evans,et al.  Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia , 2000, Leukemia.

[37]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Furman,et al.  Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. , 2000, Circulation.

[39]  Kaoru Kobayashi,et al.  CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.

[40]  E. Nanba,et al.  Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. , 2000, Pharmacogenetics.

[41]  M. Fromm,et al.  P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. , 2000, International journal of clinical pharmacology and therapeutics.

[42]  U. Brinkmann,et al.  How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport , 2000, Clinical chemistry and laboratory medicine.

[43]  E S Lander,et al.  The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. , 2000, Nature genetics.

[44]  B. Sarkadi,et al.  An inventory of the human ABC proteins. , 1999, Biochimica et biophysica acta.

[45]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[46]  D. Nebert,et al.  Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? , 1999, Clinical genetics.

[47]  R. Oertel,et al.  Intestinal secretion of intravenous talinolol is inhibited by luminal R‐verapamil , 1999, Clinical pharmacology and therapeutics.

[48]  J. Brockmöller,et al.  Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. , 1999, British journal of clinical pharmacology.

[49]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.

[50]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[51]  J. Pritchard,et al.  Use of unlinked genetic markers to detect population stratification in association studies. , 1999, American journal of human genetics.

[52]  G. Aithal,et al.  Warfarin dose requirement and CYP2C9 polymorphisms , 1999, The Lancet.

[53]  Nicholas Schork,et al.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment , 1999, Nature Genetics.

[54]  G R Wilkinson,et al.  Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. , 1999, Circulation.

[55]  M C Meyer,et al.  Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. , 1999, Pharmacogenetics.

[56]  M. Pirmohamed,et al.  The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. , 1999, Pharmacogenetics.

[57]  Freely associating , 1999, Nature Genetics.

[58]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[59]  E. Yukawa,et al.  The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics , 1998, Epilepsia.

[60]  J. Connell,et al.  ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. , 1998, Circulation.

[61]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[62]  H. Echizen,et al.  Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes , 1998, Clinical pharmacology and therapeutics.

[63]  P. Bray,et al.  PlA2 polymorphism and efficacy of aspirin , 1998, The Lancet.

[64]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[65]  J. Brockmöller,et al.  Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. , 1998, Pharmacogenetics.

[66]  M. Eichelbaum,et al.  Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. , 1998, Pharmacogenetics.

[67]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[68]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[69]  A. Seelig.  A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.

[70]  Arya M. Sharma,et al.  Association of a human G-protein β3 subunit variant with hypertension , 1998, Nature Genetics.

[71]  W. Trager,et al.  Genetic association between sensitivity to warfarin and expression of CYP2C9*3. , 1997, Pharmacogenetics.

[72]  K. Furusho,et al.  Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy , 1997, Clinical pharmacology and therapeutics.

[73]  L. Benet,et al.  Tacrolimus oral bioavailability doubles with coadministration of ketoconazole , 1997, Clinical pharmacology and therapeutics.

[74]  Cristina Barlassina,et al.  Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension , 1997, The Lancet.

[75]  P. Borst,et al.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Miners,et al.  Allelic and functional variability of cytochrome P4502C9. , 1997, Pharmacogenetics.

[77]  L Zagato,et al.  Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. , 1997, Lancet.

[78]  M. Takano,et al.  Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. , 1996, Biological & pharmaceutical bulletin.

[79]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[80]  C. Beglinger,et al.  Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation , 1996, British journal of pharmacology.

[81]  D A Smith,et al.  Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[82]  S. Gauthier,et al.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[83]  H Furuya,et al.  Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. , 1995, Pharmacogenetics.

[84]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[85]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[86]  N K Spurr,et al.  A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. , 1995, Genomics.

[87]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[88]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.

[89]  Chuan Yi Tang,et al.  A 2.|E|-Bit Distributed Algorithm for the Directed Euler Trail Problem , 1993, Inf. Process. Lett..

[90]  K. Korzekwa,et al.  Predicting the cytochrome P450 mediated metabolism of xenobiotics. , 1993, Pharmacogenetics.

[91]  K. Chiba,et al.  Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. , 1992, The Journal of pharmacology and experimental therapeutics.

[92]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[93]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[94]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[95]  F. Guengerich,et al.  Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. , 1987, The Journal of pharmacology and experimental therapeutics.

[96]  D W Nebert,et al.  The P450 gene superfamily: recommended nomenclature. , 1987, DNA.

[97]  Michael M. Gottesman,et al.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.

[98]  P. Poffenbarger,et al.  Pharmacogenetics of Tolbutamide Metabolism in Humans , 1978, Diabetes.

[99]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[100]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[101]  A. B. Hill.  The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[102]  E. Bird,et al.  PROLONGED HYPOGLYCEMIA SECONDARY TO TOLBUTAMIDE. , 1965, Annals of internal medicine.

[103]  F. Vogel.  Moderne Probleme der Humangenetik , 1959 .

[104]  P. Carson,et al.  Enzymatic deficiency in primaquine-sensitive erythrocytes. , 1956, Science.

[105]  H. Lehmann,et al.  The familial incidence of low pseudocholinesterase level. , 1956, Lancet.

[106]  A. E. Garrod.  Inborn Errors of Metabolism , 1971 .

[107]  M. Zago,et al.  Influence of functional MDR 1 gene polymorphisms on P-glycoprotein activity in CD 34 + hematopoietic stem cells , 2022 .